Optimization of electrode montage for brain targeting and individual subject customization has never been as easier as with Soterix Medical's Neurotargeting software. With recognition that placing an electrode "over" a target does not support rational tDCS dose design, the Soterix Medical suite of software tools allow simple and automatic optimization. Optimized dose can then be loaded directly into your Soterix tDCS and HD-tDCS stimulator. Soterix Neruotargeting software also provides high-resolution current flow visualization that can be used to support publications, presentations and proposals.
Soterix Medical's revolutionary non-invasive targeting software
Rationally plan tDCS Clinical Trials
Access your trials from anywhere
Neurotargeting is not neuronavigation. Neuronavigation assists in the placing of electrodes or coils "over" brain regions. Neurotargeting automatically pre-determines the optimal electrode placement based on clinician identified brain targets and subject specific anatomy. The electrode montage (based on EEG 10/10) parameters can then be programmed into Soterix Medical HD-tDCS stimulators to achieve optimal brain current flow. Soterix Medical image processing captures true 1 mm anatomical resolution and cortical folding while custom current-flow optimization provides the precise best configuration. Neurotargeting yields a true optimized stimulation montage and the high-resolution current flow visualization to prove it.
Soterix Medical introduces a revolution in non-invasive brain targeting and specificity. HDTargets™ automatically determines the best HD configuration for any brain target. Targeting in three easy steps:
Only from Soterix Medical, HDExplore allows clinicians and researchers to investigate brain targeting for your own HD configurations. HDExplore allows clincians and researchers to rationally plan HD protocols.
Every Soterix Medical Neurotargeting software is enabled for individual optimization of current flow. Using Soterix Medical solutions, simply upload subject-specific MRIs and the corresponding current flow head model will then appear inside the subject select drop-down menu in your software. It is that easy to consider how variations in your subjects anatomy may influence current flow. Then combine this with Soterix Medical Neurotargeting to optimize electrode montage. For each of the four stroke subjects below, see how optimized Soterix HD-tDCS dosage delivers current to target regions (black circle) as opposed to conventional stimulation.
HD-tDCS clinical trial underway for fibromyalgia at Harvard Medical School and Spaulding Rehabilitation Hospital, Boston.
NIH grants Soterix a Phase-1 STTR grant to develop HD-tDCS for stroke rehabilitation. The first technology capable of delivering therapeutic direct current to target brain regions involved in functional recovery.
For the most comprehensive tDCS trial to-date, researchers selected the most advanced tDCS device and the only system optimized for clinical trials – The Soterix Medical 1x1-CT.
Epilepsy Foundation awards a New Therapy Grant for a clinical trial of High-Definition tDCS in pediatric epilepsy. Dr. Alexander Rotenberg will lead a team of clinical investigators including at BCH and Harvard Medical School.
NIH grants Burke Medical Research Institute $3m to conduct the most controlled trial of tDCS for stroke rehabilitation to date. The Soterix Medical 1x1 platform is the most advanced and the industry standard for tDCS clinical trials for rehabilitation.
Soterix Medical Inc. receives FDA Clinical Trial IDE for High-Definition tDCS (HD-tDCS) to improve IQ in pediatric Down syndrome. HD-tDCS is the only non-invasive, brain targeted, and low-intensity technology designed to promote neuroplasticity.
Dr. Bernadette Gillick's Pediatric Rehabilitation Laboratory is supported by the NIH and University of Minnesota Clinical and Translational Science Institute to investigate the use of a form of tDCS for interventions in rehabilitation for children. Subject specific analysis with Soterix Medical Neurotargeting™ will guide current to brain cells in the injured part of the brain.
